Department of Biochemistry, Memorial University of Newfoundland, Canada.
Discipline of Pediatrics, Memorial University of Newfoundland, Canada; University of Ottawa, Children's Hospital of Eastern Ontario, Canada.
Blood Rev. 2021 Mar;46:100734. doi: 10.1016/j.blre.2020.100734. Epub 2020 Jul 14.
Extracellular vesicles (EVs) are nanosized membrane-bound particles released from all living cells examined thus far. EVs can transfer information in the form of proteins, nucleic acids, and lipids from donor cells to recipient cells. Here we summarize recent advances in understanding the role(s) EVs play in hematological malignancies (HM) and outline potential prognostic and diagnostic strategies using EVs. EVs have been shown to promote proliferation and angiogenesis, and alter the bone marrow microenvironment to favour the growth and survival of diverse HM. They also promote evasion of anti-cancer immune responses and increase multi-drug resistance. Using knowledge of EV biology, including HM-specific packaging of cargo, EV based diagnostics and therapeutic approaches show substantial clinical promise. However, while EVs may represent a new paradigm to solve many of the challenges in treating and/or diagnosing HM, much work is needed before they can be used clinically to improve patient outcomes.
细胞外囊泡 (EVs) 是迄今为止从所有研究过的活细胞中释放的纳米级膜结合颗粒。EVs 可以以蛋白质、核酸和脂质的形式将信息从供体细胞传递到受体细胞。在这里,我们总结了对 EV 在血液系统恶性肿瘤 (HM) 中作用的最新认识,并概述了使用 EV 的潜在预后和诊断策略。EVs 已被证明可促进增殖和血管生成,并改变骨髓微环境,有利于各种 HM 的生长和存活。它们还促进了抗癌免疫反应的逃逸,并增加了多药耐药性。利用 EV 生物学知识,包括 HM 特异性货物包装,基于 EV 的诊断和治疗方法具有很大的临床应用前景。然而,虽然 EVs 可能代表了解决治疗和/或诊断 HM 中许多挑战的新范例,但在它们能够用于临床改善患者预后之前,还需要做大量工作。